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and Andrea McCoy1
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Abstract. Here we report the first incidence of New Delhi metallo-β-lactamase (NDM-1)–producing Acinetobacter
baumannii in Peru, identified via a strain-based nosocomial surveillance project carried out in Lima and Iquitos. The blaNDM-1
genewasdetectedbymultiplexpolymerasechain reaction (PCR) andconfirmedby loci sequencing.Acinetobacter baumannii
is anearly ubiquitousandpromiscuousnosocomial pathogen, and theacquisitionofblaNDM-1byA.baumanniimay facilitatean
increase in the prevalence of this important resistance marker in other nosocomial pathogens.
INTRODUCTION
Health-care–associated infections (HAI) and antimicrobial re-
sistance are of great public health concern worldwide.1 Bacterial
pathogenscausingHAIhavebecome increasinglymore resistant
over the past 10–15 years as a result of various mechanisms,
including gene-mediated enzymes such as class A, B, and D
β-lactamases.2 Numerous factors, from the horizontal transfer of
gene-encodedenzymes toglobal travel, have allowed resistance
and resistant organisms to rapidly spread with great clinical and
epidemiological impact.3,4 The recently described carbapene-
mase, New Delhi metallo-β-lactamase (NDM-1) class B, is of
particular epidemiological and clinical concern. Since its dis-
covery in2008,NDM-1has rapidlyspreadworldwideandconfers
resistance toalmostall lactams,with theexceptionof aztreonam,
leaving limited therapeutic options against pathogens harboring
NDM-1, typically colistin, tigecycline, and fosfomycin.2,5,6 In Latin
America, the blaNDM-1 gene was first reported in 2011 from
GuatemalaandColombia, and later fromMexico in2012,Brazil in
2013, and Uruguay in 2013, with all instances from Enter-
obacteriaceae.5 The blaNDM-1 gene in non-fermentative patho-
gens was first reported in Latin America from Honduras
(Acinetobacter baumannii) and Paraguay (Acinetobacter pittii) in
2012, and later from Brazil (A. baumannii) in 2014, Cuba (Acine-
tobacter soli) in 2015, Argentina (Acinetobacter junii) in 2016, and
Colombia (A. baumannii) in 2017.5–8 In Peru, the first report of
blaNDM-1 was in May 2017 in a set of nine Klebsiella pneumoniae
infecting or colonizing critically ill neurological patients from one
hospital in Lima.9 Here, we describe the identification of the first
three strains ofA. baumanniiharboringblaNDM-1 inPeru as part of
a strain-based surveillance project carried out by the Naval
Medical Research Unit No Six (NAMRU-6) in Lima, Peru.
MATERIALS AND METHODS
In June 2016, NAMRU-6 began ongoing strain collection
from Lima (three hospitals) and Iquitos (two hospitals), Peru.
Strain collection for this effort focuses on, but is not limited to,
multidrug-resistant or extremely drug-resistant (MDR/XDR)
ESKAPE pathogens (Enterococcus faecium, Staphylococcus
aureus, K. pneumoniae, A. baumannii, Pseudomonas aerugi-
nosa, and Enterobacter spp.), described as the most impor-
tant pathogens causing HAI globally.10
At participating hospitals in Lima and Iquitos, clinicians order
sampling and cultures as part of routine patient care (hemo-
culture, wound swabs, secretion sampling, catheter tip cultures,
etc.), and the local hospital laboratory or infection control pro-
gram isolates and identifies the etiology of the infection, as well
as performs susceptibility testing. Briefly, at both sites, con-
ventional culture procedures are performed for identification and
susceptibility testing using routine biochemical algorithms and
disk diffusion tests, respectively. In addition, at the participating
hospital in Lima, isolates from bacteremic patients were re-
covered using the automatedBDBACTECbloodculture system
and identification and susceptibilities were confirmed using a
Phoenix system (Becton & Dickinson Diagnostics, Sparks, MD).
Once isolates are identified at the participating hospital
laboratory, the strains are cryopreserved and transferred
within 2 weeks to NAMRU-6 for confirmation and further
molecular characterization. No clinical, epidemiological, or
personally identifiable data are obtained by NAMRU-6; only
limited data about how a strain was isolated are reported.
At NAMRU-6, all strains such as those reported here are
confirmed by routine biochemical algorithms and matrix-
assisted laser desorption/ionization-time-of-flight (MALDI-
TOF) (Becton & Dickinson Bruker Microflex, Bremen,
Germany). Antibiotic susceptibility testing (AST) is performed
by using the disk diffusion test and the Phoenix system (BD
Diagnostics, Sparks, MD), and results are interpreted using
the Clinical Laboratory Standards Institute guidelines.11
Molecular characterization of strains is performed on highly
resistant MDR/XDR pathogens as described by Magiorakos
et al.12 Each MDR/XDR isolate is first characterized by multi-
plex PCR. Colony PCR and cycling conditions are performed
essentially as described by Poirel et al.,13 using the following
primers that amplify loci within each open reading frame as
described previously13,14:
IMP-F: 59-GGAATAGAGTGGCTTAAYTCTC-39, IMP-R: 39-
GTTTAAYAAAACAACCACC-59 (232 bp); VIM-F: 59-GATGG
TGTTTGGTCGCATA-39, VIM-R: 39-CGAATGCGCAGCAC
CAG-59 (390 bp); NDM-F: 59-GGTTTGGCGATCTGGTTTTC-
39, NDM-R: 39-CGGAATGGCTCATCACGATC-59(621 bp);
* Address correspondence to Claudio Rocha, Universidad Autonoma
de Barcelona, Barcelona, Spain, E-mail: claudiorochacalderon@
gmail.com or James Regeimbal, Hospital Naval, Av. Venezuela
cuadra 36 S/N, Bellavista, Callao, Peru, E-mail: james.m.regeimbal.
mil@mail.mil.
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and KPC-F: 59-CGTCTAGTTCTGCTGTCTTG-39, KPC-R:
39-CTTGTCATCCTTGTTAGGCG-59 (798 bp).
Cleaned colony PCR products from each PCR-positive isolate
are then subjected to amplicon sequencing using an ABI 3130XL
geneticanalyzer (AppliedBiosystems,NewYork,NY)according to
the manufacturer’s protocol, using the same primers listed pre-
viously. Sequence analysis is performed using Sequencher V5.4
GeneCodesCorporation (AnnArbor,MI)andbasic localalignment
search tool (BLAST, National Center for Biotechnology In-
formation) to compare obtained target sequences with the data-
base. Thus, MDR/XDR strains are characterized by NAMRU-6 for
phenotypic andgenotypic resistance to the partial sequence level.
RESULTS
From June 2016 to November 2017, 875 ESKAPE and 213
Escherichia coli isolates were collected from Lima and Iquitos
hospitals (Table 1). The most frequent pathogen collected
from Lima was P. aeruginosa (36%), whereas that of Iquitos
was E. coli (46%). Enterobacteriaceae (K. pneumoniae,
Enterobacter spp., and E. coli) represented 45% of all patho-
gens collected, whereas A. baumannii represented 11%.
From the total 1,088 strains collected, 978 were Gram-
negative pathogens and AST was performed on 974. Of the
974 isolates, 472 (48%) were non-susceptible (resistant or
intermediate phenotype) to carbapenem. PCRwas performed
on 764 (78%) of the 974 strains with AST results, and 155
(20%) of those were positive for at least one of the four
carbapenemase-encoding genes tested. Interestingly, 8 (5%)
strains harboring PCR-detectable carbapenemase-encoding
geneswere susceptible to carbapenems, indicating not only a
general agreement between PCR and AST but also that there
are pseudogenes for carbapenem resistance present in the
susceptible clinical isolates here. Such sequences likely have
an interesting role in the dynamics of resistance within bac-
terial populations, and further analysis of such sequences in
populations of clinical isolates in Peru is needed. From these
155 strains, an additional eight non-susceptible strains har-
boring blaNDM-1 were detected: five Enterobacteriaceae (one
E. coli and four K. pneumoniae, all from Lima) and three
A. baumannii (one from Lima and two from Iquitos).
The only A. baumannii harboring blaNDM-1 from Lima was
isolated in January 2017 from a hemoculture taken in a tertiary
care oncology hospital and was classified as MDR using the
same criteria as previously mentioned.12 The strain was re-
sistant to all β-lactams with the exception of aztreonam, to
which it showed intermediate resistance. This strain was also
resistant to all the carbapenems tested, as well as to
fosfomycin. In addition, the strain showed intermediate re-
sistance to tetracycline but was sensitive to quinolones,
aminoglycosides, trimethoprim–sulfamethoxazole, and co-
listin (Table 2). The two A. baumannii strains from Iquitos
harboring blaNDM-1 were isolated from the same tertiary care
general hospital but at different times and from different types
of infections. The first was also isolated in January 2017 froma
central venous catheter tip and was classified as MDR. This
strain was resistant to all β-lactams with the exception of
piperacillin–tazobactam, to which it showed intermediate re-
sistance, and itwasalso resistant to all the carbapenems tested
and fosfomycin. In addition, this strain also showed in-
termediate resistance to ciprofloxacin but was sensitive to
tetracycline, trimethoprim–sulfamethoxazole, levofloxacin,
aminoglycosides, and colistin. The second A. baumannii from
Iquitos was isolated in February 2017 from a postsurgical
wound and was classified as XDR. This strain was resistant to
all the antibiotics tested except ampicillin–sulbactam, to which
it showed intermediate resistance, andcolistin and tetracycline,
to which it was sensitive (Table 2). Amplicon sequencing of all
three A. baumannii strains returned a 99%match to blaNDM-1.
DISCUSSION
Carbapenem-resistant A. baumannii is a serious public health
concern worldwide.2,6,15,16 Acinetobacter baumannii has spread
throughout the world acquiring antibiotic resistance, first to the
most common antibiotics (β-lactams, sulfonamides, and
aminoglycosides) and later to carbapenems.15,17,18 The clinical
TABLE 1
ESKAPE strains and Escherichia coli collected from June 2016 to
November 2017 from Lima and Iquitos, Peru
ESKAPE Lima Iquitos Total
Enterococcus faecium 20 0 20 (1.8%)
Enterobacter spp. 38 2 40 (3.7%)
Staphylococcus aureus 80 10 90 (8.3%)
Acinetobacter baumannii 116 8 124 (11.4%)
Klebsiella pneumoniae 204 34 238 (21.9%)
Pseudomonas aeruginosa 343 20 363 (33.4%)
Total (ESKAPE) 801 74 875 (80.4%)
E. coli 150 63 213 (19.6%)
Total (ESKAPE and E. coli) 951 137 1,088
ESKAPE = Enterobacter spp., S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, and
E. faecium.
TABLE 2
Resistance pattern of the three strains of Acinetobacter baumannii
harboring blaNDM-1 gene
Code NSC2058 NSI1409 NSI1428
Study site Lima Iquitos Iquitos
Sample type Hemoculture CVC tip Wound
Sample date January 27,
2017
January 18,
2017
January 17,
2017
AMK S S R
GEN S S R
AMP R R R
SAM R R I
TIC R R R
TIM R R R
TZP R I R
ATM I R R
CAZ R R R
CFZ R R R
CRO R R R
FOX R R R
FEP R R R
LVX S S R
CIP S I R
IPM R R R
MEM R R R
FOF R R R
SXT S S R
TET I S S
CST S S S
Definition for
acquired
resistance
MDR MDR XDR
AMK= amikacin; AMP= ampicillin; ATM= aztreonam; CAZ = ceftazidime; CFZ = cefazolin;
CIP = ciprofloxacin; CRO= ceftriaxone; CST = colistin; CVC = central venous catheter; FEP =
cefepime; FOF = fosfomycin; FOX = cefoxitin; GEN = gentamicin; I = intermediate; IPM =
imipenem; LVX = levofloxacin;MDR=multidrug resistant; MEM=meropenem;NDM-1=New
Delhi metallo-β-lactamase; R = resistant; S = sensitive; SAM = ampicillin–sulbactam; SXT =
trimethoprim–sulfamethoxazole; TET = tetracycline; TIC = ticarcillin; TIM = ticarcillin-
clavulanic acid; TZP = piperacillin–tazobactam; XDR = extremely drug resistant.
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impact of this pathogen stems from its ability to upregulate or
readily acquire resistance determinants and survive for pro-
longedperiods innosocomial environments, thusenhancing its
rapid dissemination.6,16,17Carbapenem-resistantA. baumannii
is mainly thought to produce OXA-β-lactamases (oxacillin-
hydrolysing) and is less frequently an NDM-1 producer.15–17
Conversely, some studies have found truncated forms of the
blaNDM-1-harboring composite transposons Tn125 in Enter-
obacteriaceae species, whereas the complete sequence can
be found in A. baumannii. Taken together, this suggests that
A. baumannii may serve as a reservoir of blaNDM-1 that can be
transferred toother pathogens.2,6,19,20 Furthermore, the spread
of A. baumannii harboring blaNDM-1 is likely not a matter of a
single lineage but may involve different contemporary clones.
NSC2058 and NSI1409 were found in Lima and Iquitos,
respectively; yet they have similar patterns of resistance for
the antibiotics tested (Table 2), and both were found in
January 2017. Together these results suggest a possible
epidemiological link, despite the fact that Iquitos can only
be reached by air or river travel and is located more than
1,000 km northeast of Lima. Conversely, NSI1428 was
found almost a month later in Iquitos and has a different
resistance pattern, suggesting this may be a different clone.
However, more sequence analysis beyond the scope here
would be required to assess the relatedness of these
strains.
We report here the first instancesofblaNDM-1 inA.baumannii
in Peru, isolated from two different and geographically distinct
regions at essentially the same time. This findinghighlights the
urgent need to implement surveillance and infection control
measures for carbapenem-resistant pathogens, not only to
mitigate the spread of resistant strains but also to limit or
prevent the transfer of these resistance markers between
pathogens in Peru and globally.1
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